A quarterly report on EDC’s expenditure, as well as, retention or designation of persons or organizations to engage in lobbying or lobbying activities before the council or any member thereof, the city planning commission, a borough president, a borough board or a community board.
A quarterly report on EDC’s expenditure, as well as, retention or designation of persons or organizations to engage in lobbying or lobbying activities before the council or any member thereof, the city planning commission, a borough president, a borough board or a community board.
A quarterly report on EDC’s expenditure, as well as, retention or designation of persons or organizations to engage in lobbying or lobbying activities before the council or any member thereof, the city planning commission, a borough president, a borough board or a community board.
A quarterly report on EDC’s expenditure, as well as, retention or designation of persons or organizations to engage in lobbying or lobbying activities before the council or any member thereof, the city planning commission, a borough president, a borough board or a community board.
A quarterly report on EDC’s expenditure, as well as, retention or designation of persons or organizations to engage in lobbying or lobbying activities before the council or any member thereof, the city planning commission, a borough president, a borough board or a community board.
A quarterly report on EDC’s expenditure, as well as, retention or designation of persons or organizations to engage in lobbying or lobbying activities before the council or any member thereof, the city planning commission, a borough president, a borough board or a community board.
Report including (1) the number of opioid antagonists available; (2) the number of staff trained to administer; (3) the number of instances during the quarter it was administered; and (4) the number of instances in which the patient responded to the administration of an opioid antagonist.
Report including (1) the number of opioid antagonists available; (2) the number of staff trained to administer; (3) the number of instances during the quarter it was administered; and (4) the number of instances in which the patient responded to the administration of an opioid antagonist.
Report including (1) the number of opioid antagonists available; (2) the number of staff trained to administer; (3) the number of instances during the quarter it was administered; and (4) the number of instances in which the patient responded to the administration of an opioid antagonist.
Report including (1) the number of opioid antagonists available; (2) the number of staff trained to administer; (3) the number of instances during the quarter it was administered; and (4) the number of instances in which the patient responded to the administration of an opioid antagonist.